Antares Pharma (ATRS) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Antares Pharma (ATRS) PT Lowered to $5 at Jefferies
November 8, 2017 8:44 AM ESTJefferies lowered its price target on Antares Pharma (NASDAQ: ATRS) to $5.00 (from $6.00) while maintaining a Buy rating.
Analyst Anthony Petrone notes ATRS reported a solid 3Q17; however the focus remains squarely on XYOSTED and other pipeline developments.
... More